Zentalis Appoints James B. Bucher as CLO, Stock Options Granted to Three
Zentalis Pharmaceuticals, Inc. has appointed James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary. Alongside two new hires, Bucher received stock options. Azenosertib, the company's lead drug, has shown promise in clinical trials.
Bucher was granted options to purchase 400,000 shares of Zentalis' common stock. The options have a 10-year term and an exercise price of $1.54 per share. They were granted under the 2022 Employment Inducement Incentive Award Plan. The two additional employees each received options for 15,000 shares. All options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the next three years, contingent on continued service.
Azenosertib, a WEE1 inhibitor, has been well-tolerated and shown anti-tumor activity in clinical trials across multiple tumor types. It is being evaluated as a monotherapy and in combination, with potential for a broad franchise.
Zentalis Pharmaceuticals, Inc. has strengthened its leadership with the appointment of James B. Bucher, JD, and two new employees. The company's lead drug, azenosertib, continues to show promise in clinical trials, paving the way for further development.
